Member Info for B_Positive

Total volume since the raise is approaching 2billion, so we are closer to around 4x churn, which is very significant.

Many operate on the basis that we need to see 2.5x churn to shift the new shares, so that's a fair cushion above that.

Far as I can see this has already done a 4x raise churn, which is very significant.

Very nice

Https://www.fiercebiotech.com/biotech/avalyn-aims-181m-ipo-fund-phase-3-trials-reformulated-respiratory-drugs

Circa £150M valuation envisaged.

My 16th April post:

"Avalyn Pharma NASDAQ IPO - Taster Of NFX Valuation Going Forward

Relative to our circa £4M market cap, NFX could well be a monster in the making when compared with peers further along the development pipeline and the total addressable market already served by certain, albeit deficient, blockbuster drugs.

Crucially, their offerings are not considered an absolute rival treatment, but rather, lead candidate NFX002 is seen as complementary whilst maintaining its unique differentiators and competitive advantages.

Below is reporting on the imminent IPO - price TBD - but if the hundreds of millions already received in prior series funding rounds is anything to go by...

https://firstwordpharma.com/story/7176371

https://www.fiercebiotech.com/biotech/avalyn-plans-ipo-fund-phase-3-trials-inhaled-versions-approved-respiratory-drugs

If you can get past the very 'American' interview, it's nevertheless an insightful watch from a few months ago.

https://www.biotechtv.com/post/avalyn-pharma-100-million-series-d-july-22-2025"

Sorry wrong board, that was for MILA Resources following their RNS.

Please delete.

Just stunning

Highest-grade gold intercept recorded on the project at 112g/t over 1m.

·      Drillholes confirm high grade mineralisation in southernmost positions drilled to date at Yarrol North Target.

·      The results also confirm extensions of shallow gold mineralisation further to the north and continuity of mineralisation to the west that was not included in the historic resource.

·      Further results from infill and step-out holes completed as part of the Q1 2026 programme are pending and will be reported in due course.

·      The programme is designed to build the dataset required for an initial JORC mineral resource estimate ("MRE").

·      Multi-element geochemical assays are being used to refine the Company's structural interpretation of the Yarrol system and to inform next-phase drill targeting.

·      Best intercepts from the three holes include:

·      4m @ 29.4g/t gold (Au) from 8m (MYARC0222)

o  including 1m @ 112g/t Au from 10m; and

o  1m @ 5g/t Au from 11m

·      9m @ 2.48g/t Au from 31m (MYARC0216)

o  including 1m @ 15.05g/t Au from 36m

·      7m @ 1.0g/t Au from 17m (MYARC0215)

o  including 1m @ 4.04g/t Au from 21m

 

Mark Stephenson, Executive Chairman, commented:

"We are delighted with these results with some notably high-grade results. Every intercept, no matter the size, is helping us build tonnage and tighten the geological picture.

 

"What is emerging is a pattern of repeating structures hosting high-grade shoots, suggesting a more continuous and robust mineralised system than was ever previously understood.  We are now moving beyond isolated results and toward the building a meaningful and economic gold resource in a proven gold district. Following our recent capital raise we will be continuing to fast track the development of this project."

 

Yeah I think around 3p and then 5p near term once the remaining assays flow in and then over 10p easily with an MRE done.

Being in Australia is key.

Look at the other gold companies with billions and tens of billions.

We'll be in update territory now as we get to the end of April and beginning of May.

NXP002 £52.8m broker value before the licencing would give about 2p a share?

£1m in cash, 5x the usual amount which is 20% of the entire market cap in cash.

Pharma licence deal with large pharma and specialist pharma signalled.

Dr Dan Gooding, Executive Director, Nuformix, said: "We are delighted to receive confirmation that Orphan Drug Designation has been granted by the FDA for our NXP002 programme in IPF, a high-mortality rare disease, in urgent need of new treatments. The granting of ODD in the United States, alongside the European EMA ODD granted in April 2025, will be valuable for the potential future licensing partners we are in discussions with and I look forward to providing further updates in due course."

Australia always fetches a premium

The drill campaign probably at over 50% complete now so would expect an update on that next week too.

Nice, pay day coming up for me so I'm looking for about 1m. Hopefully they don't drop the EL next week around the webinar otherwise that 1m may cost me around £10,000 rather than around £3,000

We'll be in update territory now as we get to the end of April and beginning of May.

NXP002 £52.8m broker value before the licencing would give about 2p a share?

£1m in cash, 5x the usual amount which is 20% of the entire market cap in cash.

Pharma licence deal with large pharma and specialist pharma signalled.

Dr Dan Gooding, Executive Director, Nuformix, said: "We are delighted to receive confirmation that Orphan Drug Designation has been granted by the FDA for our NXP002 programme in IPF, a high-mortality rare disease, in urgent need of new treatments. The granting of ODD in the United States, alongside the European EMA ODD granted in April 2025, will be valuable for the potential future licensing partners we are in discussions with and I look forward to providing further updates in due course."

Directors keeping locking away their shares into more tax efficient accounts through 2026 which to me implies that they anticipate very large profits and want to reap the maximum benefits of this.

So much coming near-term

Firstly I suspect the TR1 holder is continuing to add given the regular rounded buying going on which was the same as before he declared his 6% position and we await confirmation.

We have drill results due from the step out drilling campaign this quarter and updates on progress

We have the webinar next week.

The Exploitation licence due this quarter.

Managem JV sounds very close to a tasty update going by this:

With regard to Senala, our 40%-owned licence in Senegal, managed by our partner, Managem, the long-awaited, joint-venture agreement is inching its way to completion. I am hopeful that it will be finally agreed and signed soon, with a work programme due to commence immediately after the agreement is executed. This licence sits within a highly endowed gold region of Senegal and we have seen some very nice grades from drilling undertaken in previous years.

A further JORC resource upgrade to MBE late Q2 / early Q3.

Company now has over 1.5million ounces of gold which is straggering.

Worth $7BIL+

Drill campaign kick off next week?

CDL 200% from here only takes it to about the recent high.

From a market cap perspective 1.45p doesn't reflect the true value of world class gold assets. Far from it.

12 month high of 1.45p to beat.

All time high of aorund 10.00p to beat.

CDLs gold assets borders the following in Australia and are literally a stones throw away.

Vault Minerals on the ASX / Ticker: VAU. Market Cap = $5BILLION. Search them up.

Northern Star Resources / Ticker: NST. Market Cap = $ $33BILLION. Search them up.

Darlot West Gold Project

From a very recent RNS:

*The Company believes there is very significant potential for this project to host significant gold mineralisation similar to that found at the Darlot Gold Mine (Vault Minerals ASX:VAU), located only 10km to the northeast and Northern Star's ( ASX:NST) Thunderbox Gold Mine 20km to the southeast. (Figure 1).

Then Crofton:

Crofton

*Initial sampling work was focused on areas of historically reported gold mineralisation where grades of up to 253 g/t Au have been historically reported. This work confirmed historical grades, with 15 samples >1 g/t and up to 162.25 g/t Au.

Those are also world class grades.

All the infastructure for gold mines are in place and the processing is there too.

CDL at 50p a share would only be at a $1bil market cap. A fraction of either.

I genuinely think this can do a 0.5 > 50p move as the drilling starts and unravels these world class assets.

Like I said even at 50p a share it would be trading at a tiny fraction of the companies this borders.

“The Company conducted studies in a new iteration of a 3D human IPF lung tissue model, that has been advanced to significantly reduce output variability, offering greater disease and species relevance.

✅NXP002 is well tolerated in ex-vivo human lung tissue with no signs of toxicity events;

✅NXP002 alone delivers a strong, consistent anti-fibrotic and anti-inflammatory effect as demonstrated by modulation of the release of multiple biomarkers of fibrosis and inflammation;

✅both high and low concentrations of NXP002 show an additive anti-fibrotic and anti-inflammatory effect to SoC;

✅in particular, the higher concentrations of NXP002 with SoC's deliver a near complete ablation of fibrosis biomarker release, yet at lower concentrations than have been seen in other preclinical models to date; and

✅the clear, pronounced additive benefit of NXP002 on top of SoCs observed suggests that NXP002 will provide additional efficacy, even in patients responding to SoC therapy.

"With regard to Senala, our 40%-owned licence in Senegal, managed by our partner, Managem, the long-awaited, joint-venture agreement is inching its way to completion. I am hopeful that it will be finally agreed and signed soon, with a work programme due to commence immediately after the agreement is executed. This licence sits within a highly endowed gold region of Senegal and we have seen some very nice grades from drilling undertaken in previous years."

News cometh

Not so sure about that given they just raised a big chunk with £1.8m last quarter.

Both Bezand and AFP are well below fair value but AFP is more below given it's pittance capitalisation

Going to add a few more here before the month is out.

So much coming near-term

Firstly I suspect the TR1 holder is continuing to add given the regular rounded buying going on which was the same as before he declared his 6% position and we await confirmation.

We have drill results due from the step out drilling campaign this quarter and updates on progress

We have the webinar next week.

The Exploitation licence due this quarter.

Managem JV sounds very close to a tasty update going by this:

With regard to Senala, our 40%-owned licence in Senegal, managed by our partner, Managem, the long-awaited, joint-venture agreement is inching its way to completion. I am hopeful that it will be finally agreed and signed soon, with a work programme due to commence immediately after the agreement is executed. This licence sits within a highly endowed gold region of Senegal and we have seen some very nice grades from drilling undertaken in previous years.

A further JORC resource upgrade to MBE late Q2 / early Q3.

Company now has over 1.5million ounces of gold which is straggering.

Worth $7BIL+

NXP002 £52.8m broker value before the licencing deal is 2p a share.

£1m in cash, 5x the usual amount which is 20% of the entire market cap in cash.

Pharma licence deal with large pharma and specialist pharma well advanced and anticipated.

Dr Dan Gooding, Executive Director, Nuformix, said: "We are delighted to receive confirmation that Orphan Drug Designation has been granted by the FDA for our NXP002 programme in IPF, a high-mortality rare disease, in urgent need of new treatments. The granting of ODD in the United States, alongside the European EMA ODD granted in April 2025, will be valuable for the potential future licensing partners we are in discussions with and I look forward to providing further updates in due course."

NXP002 £52.8m broker value before the licencing deal is 2p a share.

£1m in cash, 5x the usual amount which is 20% of the entire market cap in cash.

Pharma licence deal with large pharma and specialist pharma well advanced and anticipated.

Dr Dan Gooding, Executive Director, Nuformix, said: "We are delighted to receive confirmation that Orphan Drug Designation has been granted by the FDA for our NXP002 programme in IPF, a high-mortality rare disease, in urgent need of new treatments. The granting of ODD in the United States, alongside the European EMA ODD granted in April 2025, will be valuable for the potential future licensing partners we are in discussions with and I look forward to providing further updates in due course."